Portal de investigación
A prospective multicenter study assessing effectiveness and safety of secukinumab in a real-life setting in 158 patients
Fecha de publicación:
Autores de IIS La Fe
Participantes ajenos a IIS La Fe
- Ortiz-Salvador, JM
- Saneleuterio-Temporal, M
- Magdaleno-Tapial, J
- Velasco-Pastor, M
- Mateu-Puchades, A
- Pitarch-Bort, G
- Mari-Ruiz, JI
- Matabi-Diaz, J
- Montesinos-Villaescusa, E
- Miralles-Botella, J
- Garcia-Fernandez, L
- Martorell-Calatayud, A
- Belinchon-Romero, I
- Sanchez-Carazo, JL
- Perez-Ferriols, A
Grupos
Abstract
Background: Secukinumab is a first-in-class interleukin 17A monoclonal antibody that has demonstrated an excellent safety and efficacy profile in phase 3 studies. Objective: To evaluate the effectiveness of secukinumab in daily clinical practice and to understand the clinical and epidemiologic characteristics of patients treated with secukinumab in clinical settings. Methods: In this multicenter prospective observational study, we recruited adult patients with moderateto- severe plaque psoriasis from 12 hospitals in Spain during January-December 2016. These patients were treated with secukinumab and prospectively followed at 12-week intervals for 52 weeks. Results: In total, 158 patients were recruited to the study. A Psoriasis Area and Severity Index (PASI) score improvement $ 75% over baseline (PASI-75) was achieved by 57%, 83.5%, 89%, and 78.5% of patients at weeks 4, 12, 24, and 52, respectively. PASI-90 was achieved in 27.8%, 62%, 64.6%, and 63.2% of patients at weeks 4, 12, 24, and 52, respectively; PASI-75 and PASI-90 responders were significantly more common among patients with a body mass index < 30 kg/cm(2) and patients without previous biologic therapy failures. Limitations: Observational study. Time from onset of psoriasis was not evaluated. Conclusion: Secukinumab is a safe treatment with effectiveness rates similar to those found in its phase 3 studies. These rates endure up to a year from start of treatment.
Datos de la publicación
- ISSN/ISSNe:
- 0190-9622, 1097-6787
- Tipo:
- Article
- Páginas:
- 427-432
- PubMed:
- 30872150
- Factor de Impacto:
- 1,811 SCImago ℠
- Cuartil:
- Q1 SCImago ℠
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY MOSBY-ELSEVIER
Citas Recibidas en Web of Science: 24
Documentos
- No hay documentos
Filiaciones
Keywords
- biologic therapy; IL-17; psoriasis; secukinumab
Cita
Ortiz JM,Saneleuterio M,Magdaleno J,Velasco M,PUJOL C,SAHUQUILLO A,Mateu A,Pitarch G,Mari JI,Matabi J,Montesinos E,Miralles J,Garcia L,Martorell A,Belinchon I,Sanchez JL,Perez A. A prospective multicenter study assessing effectiveness and safety of secukinumab in a real-life setting in 158 patients. J. Am. Acad. Dermatol. 2019. 81. (2):p. 427-432. IF:8,277. (1).